Coloplast A/S banner

Coloplast A/S
OTC:CLPBF

Watchlist Manager
Coloplast A/S Logo
Coloplast A/S
OTC:CLPBF
Watchlist
Price: 66.5 USD -3.09% Market Closed
Market Cap: $14.9B

EV/OCF

16.7
Current
61%
Cheaper
vs 3-y average of 43.1

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
16.7
=
Enterprise Value
$128.3B
/
Operating Cash Flow
kr6.9B

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
16.7
=
Enterprise Value
$128.3B
/
Operating Cash Flow
kr6.9B

Valuation Scenarios

Coloplast A/S is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (43.1), the stock would be worth $171.64 (158% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-30%
Maximum Upside
+158%
Average Upside
66%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 16.7 $66.5
0%
3-Year Average 43.1 $171.64
+158%
5-Year Average 41.6 $165.69
+149%
Industry Average 14.3 $56.76
-15%
Country Average 11.7 $46.73
-30%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
DK
Coloplast A/S
OTC:CLPBF
95.4B USD 16.7 23.8
US
Medline Inc
NASDAQ:MDLN
60.7B USD 0 0
JP
Hoya Corp
TSE:7741
9.6T JPY 36.1 38.5
CH
Alcon AG
SIX:ALC
29.4B CHF 17.6 37.7
US
Align Technology Inc
NASDAQ:ALGN
13.6B USD 21.1 33.2
UK
ConvaTec Group PLC
LSE:CTEC
4.4B GBP 15.4 33.2
CA
Bausch + Lomb Corp
NYSE:BLCO
5.6B USD 36.1 -15.5
JP
Asahi Intecc Co Ltd
TSE:7747
880.1B JPY 20.5 49.8
KR
HLB Inc
KOSDAQ:028300
8T KRW -86.9 -36.4
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.3B USD 14.3 22.9
CN
Intco Medical Technology Co Ltd
SZSE:300677
36.4B CNY 18.5 21.4
P/E Multiple
Earnings Growth PEG
DK
Coloplast A/S
OTC:CLPBF
Average P/E: 32.5
23.8
21%
1.1
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.5
15%
2.6
CH
Alcon AG
SIX:ALC
37.7
32%
1.2
US
Align Technology Inc
NASDAQ:ALGN
33.2
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
33.2
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
49.8
40%
1.2
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.4 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
22.9
30%
0.8
CN
Intco Medical Technology Co Ltd
SZSE:300677
21.4
12%
1.8

Market Distribution

Lower than 82% of companies in Denmark
Percentile
18th
Based on 392 companies
18th percentile
2.6
Low
0.4 — 6.1
Typical Range
6.1 — 16.6
High
16.6 —
Distribution Statistics
Denmark
Min 0.4
30th Percentile 6.1
Median 11.7
70th Percentile 16.6
Max 4 948.3

Coloplast A/S
Glance View

Coloplast A/S, headquartered in Humlebæk, Denmark, has a storied history that dates back to 1954 when a nurse, Elise Sørensen, identified a crucial need in the healthcare sector. Her sister had undergone ostomy surgery, and the lack of appropriate post-operative care products inspired Sørensen to design the world’s first adhesive ostomy bag. This innovation laid the groundwork for Coloplast's trajectory in the healthcare industry. Today, the company has expanded its focus to include ostomy care, continence care, wound and skin care, and interventional urology. With a commitment to improving patients' quality of life, Coloplast has become a leader in designing and manufacturing products that not only highlight practicality but also embody comfort and discretion. Coloplast generates revenue through a business model that emphasizes product innovation and direct engagement with healthcare providers and patients. The company invests significantly in research and development to improve and widen its product offerings continuously. It operates globally, distributing its products directly and via partnerships with hospitals, clinics, and healthcare professionals. By maintaining an attentive approach to user experience and incorporating customer feedback into its development processes, Coloplast ensures its portfolio aligns with the actual needs of its users. This user-centered strategy not only enhances customer loyalty but also fortifies the company’s market position, driving its financial success.

CLPBF Intrinsic Value
111.32 USD
Undervaluation 40%
Intrinsic Value
Price $66.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett